ERNA-101 On Track for Q3 2026 IND Submission, First-in-Human Study; Preclinical Data Strong
ERNA sits 98% above its 52-week low of $3.183.
Summary
Ernexa Therapeutics announced its lead candidate, ERNA-101, is on track for a Q3 2026 IND submission and Q4 2026 first-in-human study, marking a transition to a clinical-stage company. This follows previous positive updates on ERNA-101's progress and comes after the company recently completed a $10.5 million financing, addressing prior liquidity concerns. Preclinical data for ERNA-101 showed complete tumor clearance and 100% long-term survival in ovarian cancer models, which is highly compelling. This progress, coupled with the financing, significantly de-risks the company's near-term development. Traders will watch for the IND submission in Q3 2026 and the start of the Phase 1 study in Q4 2026.
At the time of this announcement, ERNA was trading at $6.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.1M. The 52-week trading range was $3.18 to $71.50. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.